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Ischemic preconditioning before lower limb
ischemia—reperfusion protects against acute lung
injury
Denis W. Harkin, MD,a,b Aires A. B. Barros D’Sa, MD,a Kevin McCallion, PhD,b
Margaret Hoper, PhD,b and F. Charles Campbell, MD,b Belfast, Ireland
Objective: Prolonged limb ischemia followed by reperfusion (I/R) is associated with a systemic inflammatory response
syndrome and remote acute lung injury. Ischemic preconditioning (IPC), achieved with repeated brief periods of I/R
before the prolonged ischemic period, has been shown to protect skeletal muscle against ischemic injury. The aim of this
study was to ascertain whether IPC of the limb before I/R injury also attenuates systemic inflammation and acute lung
injury in a fully resuscitated porcine model of hind limb I/R.
Methods: This prospective, randomized, controlled, experimental animal study was performed in a university-based animal
research facility with 18 male Landrace pigs that weighed from 30 to 35 kg. Anesthetized ventilated swine were
randomized (n  6 per group) to three groups: sham-operated control group, I/R group (2 hours of bilateral hind limb
ischemia and 2.5 hours of reperfusion), and IPC group (three cycles of 5 minutes of ischemia/5 minutes of reperfusion
immediately preceding I/R). Plasma was separated and stored at 70° C for later determination of plasma tumor
necrosis factor- and interleukin-6 with bioassay as markers of systemic inflammation. Circulating phagocytic cell
priming was assessed with a whole blood chemiluminescence assay. Lung tissue wet-to-dry weight ratio and myeloper-
oxidase concentration were markers of edema and neutrophil sequestration, respectively. The alveolar-arterial oxygen
gradient and pulmonary artery pressure were indices of lung function.
Results: In a porcine model, bilateral hind limb (I/R) injury significantly increased plasma interleukin-6 concentrations,
circulating phagocytic cell priming, and pulmonary leukosequestration, edema, and impaired gas exchange. Conversely,
pigs treated with IPC before the onset of the ischemic period had significantly reduced interleukin-6 levels, circulating
phagocytic cell priming, and experienced significantly less pulmonary edema, leukosequestration, and respiratory failure.
Conclusion: Lower limb IPC protects against systemic inflammation and acute lung injury in lower limb I/R injury. (J
Vasc Surg 2002;35:1264-73.)
Surgical procedures, including limb vascular recon-
struction and operations with tourniquet, subject the limb
to prolonged periods of ischemia followed by reperfusion
(I/R). Although skeletal muscle has a higher tolerance to
warm ischemia than do many tissues, prolonged I/R leads
to local skeletal muscle injury and tissue edema.1 Experi-
mental models of I/R injury have identified the polymor-
phonuclear as playing a central role in mediating local limb
skeletal muscle injury.2 Reperfusion injury has been shown
to initiate a systemic inflammatory response syndrome,
which is characterized by proinflammatory mediator pro-
duction and circulating polymorphonuclear leukocyte acti-
vation.3 Leukosequestration with activated polymorpho-
nuclear in the pulmonary microvasculature is central to the
development of acute lung injury, acute respiratory distress
syndrome (ARDS), witnessed after limb I/R,4 and indeed
polymorphonuclear depletion has been shown to protect
against such injury.5
Ischemic preconditioning (IPC) refers to a mechanism
whereby brief periods of I/R render a tissue relatively
resistant to the harmful effects of a subsequent prolonged
period of ischemia.6 This phenomenon was first described
by Murry, Jennings, and Reimer,7 who showed that IPC
decreased infarct size induced with 40 minutes of coronary
artery occlusion in a canine model of myocardial ischemia.
Subsequent studies have shown the benefits of IPC in many
other tissues, such as skeletal muscle,8 kidney,9 liver,10
lung,11 and mesenteric endothelium.12 Remote myocardial
protection has been shown with preconditioning myocar-
dial,13 skeletal muscle,14 and even intestinal tissue.15 More
recently, myocardial preconditioning has been shown to
improve lung preservation in patients for valve replace-
ment, the mechanism suggested being caused by a reduc-
tion in polymorphonuclear leucocyte accumulation and
oxidative injury in the lung.16 A number of neuroendocrine
and paracrine triggers are released or operate during
preconditioning ischemia. This list includes adenosine,17
acetylcholine,18 catecholamines,19 angiotensin II,20 brady-
kinin,21 endothelin,22 and opiods.23 Which triggers are
involved and to what extent they contribute to precondi-
tioning may vary between species.
The aim of this study was to test the hypothesis that
IPC could limit the systemic inflammatory response to
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lower limb I/R in a fully resuscitated porcine model. Fur-
ther, the aim was that it would also attenuate acute lung
injury in this model. Systemic inflammation was character-
ized with systemic interleukin-6 concentrations, a reliable
indicator of systemic inflammation shown to correlate with
mortality and septic complications, and systemic tumor
necrosis factor (TNF)-, an important early proinflamma-
tory cytokine. Hemodynamics and lung oxygen transport
also were measured. Acute lung injury was determined with
measuring the content of myeloperoxidase as a marker of
neutrophil infiltration and tissue wet-to-dry weight ratio as
a marker of edema.
MATERIALS AND METHODS
Experimental protocol. These studies were per-
formed in accordance with the Animals (Scientific Proce-
dures) Act 1986 and with approval of our institution’s
Animals Research Committee. Immature male large white
Landrace pigs (28 to 35 kg; 6 to 8 weeks old) were deprived
of food other than water overnight before surgery.
Anesthesia and ventilation. The pigs were sedated
with intramuscular Stresnal (Azaperone BP; 2 to 3 mg/kg),
and anesthesia was induced with intravenous Sagatal (sodi-
um pentobarbital; 20 mg/kg) and maintained with a con-
tinuous intravenous infusion of Sagatal (sodium pentobar-
bital; 8 mg/kg/h), titrated to maintain apnea. After
creation of a tracheostomy with insertion of No. 7.5 endo-
tracheal tube, mechanical ventilation (tidal volume; 15
mL/kg) was instituted with an anesthesia machine. The
ventilatory rate was adjusted to maintain the arterial partial
pressure of CO2 at 30 to 42 mm Hg. End-expiratory
pressure was zero. The fraction inspired O2 concentration
was adjusted according to the experimental protocol. A
continuous infusion of compound sodium lactate (Hart-
mann’s solution, Baxter Healthcare Ltd, London, United
Kingdom; 15 mL/kg/h) was given from induction of
anesthesia throughout experiments. Heating blankets were
used to ensure body temperature of 38.2°C  0.8°C,
monitored with rectal probe and Model 7835A: Hewlett-
Packard Patient Monitor (Hewlett-Packard, Andover, Mass).
Physiologic measurement. The left carotid artery was
exposed surgically, and vascular polyethylene catheters
(PE-190, Thomas, Philadelphia, Pa) were positioned in the
left external carotid artery. Continuous arterial blood pres-
sure was monitored with electronic transduction. Intermit-
tent arterial blood gas sampling and systemic blood sam-
pling were performed. A balloon-tip pulmonary artery
catheter was advanced through the left external jugular vein
and guided into the pulmonary artery with pressure wave-
form analysis for central venous pressure (CVP), pulmonary
artery pressure (MPAP), and intermittent pulmonary arte-
rial wedge pressure monitoring. Mean pressures were de-
termined with calibrated physiologic pressure transducers
(Model 1280C) driving an amplifier monitor (Model
7835A; Hewlett-Packard). The left cephalic vein was ex-
posed surgically, and a vascular polyethylene catheter (PE-
160; Thomas) was inserted for continuous intravenous
infusions of sodium pentobarbital (0.06 mg/kg/min) and
compound sodium lactate solution (Hartmann’s solution,
Baxter).
Surgical procedures. After a midline laparotomy inci-
sion, a 14F silicon urinary catheter was placed in the blad-
der through a cystostomy and secured in place with a
purse-string suture for measurement of hourly urine out-
put. A 7F catheter was advanced through the splenic vein to
the portal vein for blood sampling. Its position was con-
firmed with palpating the tip of the catheter through the
wall of the portal vein. After hemostasis was assured, the
laparotomy was closed. The operative procedures lasted
approximately 60 minutes. The pigs’ conditions were al-
lowed to stabilize for 30 minutes after the operative proce-
dures. Stability was defined as constant heart rate, arterial
pressure, and end-tidal CO2.
Pressure measurements. Intravascular pressure read-
ings were obtained every 15 minutes for core temperature,
mean arterial blood pressure (MABP), MPAP, pulmonary
capillary wedge pressure, and CVP.
Blood gas measurements. Blood was obtained every
30 minutes from the carotid artery for measurements of
arterial partial pressure of O2. The gas analysis of the arterial
sample was performed in an automatic blood gas analyzer
(1304 pH/blood gas analyzer, Instrumentation Labora-
tory, Warrington, United Kingdom) without delay. The
partial pressure of oxygen and carbon dioxide, and hydro-
gen ion concentration, were measured, and the bicarbonate
concentration was calculated.
Fraction inspired oxygen. The fraction inspired oxy-
gen level was measured in a ventilatory circuit with an
Ohmeda 4700 Oxycap Monitor (Ohmeda, Louisville,
Colo).
Arterial-alveolar gradient. The arterial-alveolar gra-
dient was measured with the following formula: alveolar-
arterial gradient  fraction inspired O2  710–(arterial
pCO2/0.8)–arterial pO2. It is a measure of lung function
with a large gradient indicative of impaired oxygen trans-
port and hence, lung injury.
Experimental design. Basal values were recorded af-
ter the 30-minute recovery period. These measurements
included heart rate, MABP, MPAP, pulmonary arterial
wedge pressure, and arterial blood gases. Blood samples
were taken from the catheter placed in the left carotid
artery. The animals were randomized into three groups
(n  6 per group).
Control group. The control (sham) group (n  6)
was maintained with anesthesia for 270 minutes with re-
cordings as for the experimental animals (see subsequent-
ly).
Ischemia-reperfusion group. In the I/R group (n 
6), the external iliac artery was isolated bilaterally and
simultaneously occluded with a stainless steel arterial
clamp. After 120 minutes of warm global ischemia, the
external iliac artery was unclamped bilaterally and allowed
to reperfuse the ischemia tissue for 150 minutes. Absence
of flow, and restoration if appropriate, was confirmed with
an ultrasonic flow probe (Transonic Systems Inc, Ithaca,
NY) applied to the vessel wall.
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Ischemic preconditioning group. In the IPC group
(n 6), the external iliac artery was isolated bilaterally and
simultaneously clamped for 5 minutes. After the 5-minute
period of ischemia, the external iliac arteries were un-
clamped for a 5-minute reperfusion period. This was re-
peated for a total of three cycles. After IPC, the animals
underwent the 120 minutes of ischemia and 150 minutes of
reperfusion period.
Blood and tissue sampling. Blood samples and mea-
surements were taken every half hour during the experi-
mental period. Blood samples were collected in heparinized
(20 units per mL blood) sterile pyrogen-free tubes. Sam-
ples were immediately transferred on ice to be centrifuged
at 200 rpm (at 4°C) for 10 minutes. Plasma then was
aliquoted into sterile cryotubes (Nunc, Intermed, Roskidle,
Denmark) and stored at 70°C until the time of assay.
Immediately after final blood samples were taken, each
animal underwent a midline thoracotomy and samples of
right lung were excised from predetermined sites. Separate
samples were either fixed in 4% formalin or placed immedi-
ately in a sterile pyrogen-free cryotube (Nunc), snap-frozen
in liquid nitrogen, and stored at 70°C until time of
histologic assessment or assay, respectively.
Luminol-enhanced chemiluminescence assay. Chemi-
luminescence was assayed with an LKB Wallac Luminometer
1251 (Wallac Oy, Finland). This instrument detects and
records the number of photons released with luminol deoxy-
genation. With the conditions used, this luminol-dependent
chemiluminescence assay represents primarily polymorpho-
nuclear respiratory burst activity when applied to whole
blood.24 To trigger a respiratory burst, assay tubes contained
100 L of phorbol 12-myristate 13-acetate. Reactions were
initiated with the automated injection of 600 L of luminol
complete medium into each reaction tube and 100 L of
blood (prediluted 1:40 in blood diluting medium). Some
reaction tubes contained 47 pmol/L of recombinant human
TNF- receptor fusion protein. All chemiluminescence assays
were performed in duplicate at 37°C.
Activity is reported as the integral of the chemilumines-
cence events registered during the initial 10 minutes of
activation. The degree of respiratory burst activity is depen-
dent on prior priming in vivo. Further, by maximally prim-
ing some samples with addition of TNF- to the diluted
whole blood, a ratio could be determined between whole
blood priming and whole blood and TNF-, thus compar-
ing in vivo priming with maximal priming.
Total white blood cell counts. Arterial blood sam-
ples were drawn into sterile glass tubes containing 0.15%
acetic acid and kept at 4°C (Vacutainer, Becton Dickinson,
Rutherford, NJ). Small aliquots of blood were set aside for
white blood cell counts and blood smear differential cell
counts that were performed as previously described.25 The
remainder of the samples was centrifuged at 500g at 4°C for
20 minutes, and the resulting plasma was stored at20°C.
Tumor necrosis factor-alpha assay. Biologically ac-
tive TNF- was bioassayed with MTT tetrazolium-based
cytotoxicity assay. TNF- sensitive WEHI 164 clone 13
cells were counted, and the cell concentration was diluted/
concentrated to a fixed 2  105 mL1 in WEHI growth
medium containing 400 L L-glutamine, 800 L Pen/
Strep, 4 mL fetal calf serum, and 35 mL Roswell Park
Memorial Institute medium (and sodium pyruvate).
100-L cells were seeded into each well of a 96-well
microtiter plate (2  105mL1 per well) and allowed to
adhere overnight at 37°C. Recombinant human TNF-
(NIBSC, Potters Bar, United Kingdom) was serially diluted
in the range 0 to 25 pg/mL in WEHI growth medium,
supplemented with actinomycin D 6 g/mL (Merck and
Co, Inc, West Point, Pa). Supernatants were diluted as
appropriate in actinomycin D-supplemented WEHI
growth medium and 50 L human TNF- standards, and
dilutants were added to wells in duplicate. After 24 hours
incubation at 37°C, 20 L MTT (Sigma, St Louis, Mo) at
a concentration of 5 mg/mL in Hank’s balanced salt solu-
tion (Gibco BRL, United Kingdom) was added to each
well. After incubation for 5 hours at 37°C, cell viability was
determined by adding 50 L 20% (volume/volume) so-
dium dodecyl sulfate in 10 mmol/L HCl to each well to
dissolve the dark blue formazan crystals. The plate then was
incubated for a further 20 hours at 37°C. Absorbance then
was read at 570 nm, and the amount of TNF- in each
sample was computed from the standard curve. Interassay
and intraassay coefficients of variation were less than 10%.
The detection limit of the assay was 0.02 pg/mL TNF-.
Interleukin-6 assay. Biologically active interleukin-6
was measured with a bioassay on the basis of the prolifera-
tion of interleukin 6-dependent B9 hybridoma cells (a
generous gift of L. Aarden, Amsterdam, The Netherlands).
Samples were serially diluted with interleukin-6 free growth
medium and dispensed in duplicate into 96-well microtiter
plates. Similarly, a standard curve ranging from 0 to 500
pg/mL was generated with recombinant human interleu-
kin-6 (British Biotechnology, Cowley, United Kingdom)
and plated out in duplicate. B9 cells were washed free of
interleukin-6 and resuspended in interleukin-6 free B9
growth medium. Standard cell suspension (2.5 104/mL)
100 L was plated into wells and incubated at 37°C for 4
days. MTT (3-[4,5-dimethylthiazol-2yl]-2,5 diphenyltet-
razolium bromide) in phosphate-buffered saline solution
(0.5 mg/mL) was added to each well followed 5 hours later
with 50 mL sodium dodecyl sulfate (20% in 0.01 mol/L
HCL). The plates were incubated for another 24 hours.
Absorbance was then read at 570 nm, and the amount of
interleukin-6 in each sample was computed from the stan-
dard curve. Interassay and intraassay coefficients of varia-
tion were less than 10%.
Measurement of lung tissue myeloperoxidase. To
determine myeloperoxidase activity in tissue, the specimen
(200 to 400 mg) was minced in a beaker containing 1 mL
of hydroxytetraacetylammonium bromide buffer on ice,
transferred to a test tube, and homogenized with a polytron
homogenizer (Philip Harris International, Ashby, Leices-
tershire, United Kingdom), three times for 30 seconds
each, on ice. After homogenization, the homogenizer was
rinsed twice with 1 mL of hydroxytetraacetylammonium
bromide. The pooled homogenate and washes were soni-
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cated for 10 seconds, freeze-thawed thrice, and centrifuged
at 40,000g for 15 minutes. The supernatant was assayed for
myeloperoxidase activity. Myeloperoxidase activity was
measured spectrophotometrically: 0.1 mL of supernatant
was combined with 2.9 mL of 50 mmol/L phosphate
buffer, pH 6.0, containing 0.167 mg/mL O-dianisidine
hydrochloride and 0.0005% hydrogen peroxide. The
change in absorbance at 460 nm was measured with a
Beckmann DU-2 spectrophotometer (Beckmann Instru-
ments, Inc, Cedar Grove, NJ). One unit of myeloperoxi-
dase activity is defined as that degrading 1 mol/L of
peroxide per minute at 25°C.
Lung tissue wet-to-dry weight ratios. Wet-to-dry
ratios of lung and skeletal muscle tissue samples (200 to
400 mg) were calculated. Each specimen was blotted dry,
weighed, then placed in a vacuum freeze dryer at 70°C
for 48 hours. Specimens then were reweighed, and the
wet-to-dry tissue weight ratio was calculated.
Statistical analysis. Summary values are expressed as
the mean  the standard error of the mean or median
(interquartile range). One-way repeated measures analysis
of variance was used to compare sequential measurements
for parametric data. Dunnett test was used to make further
comparisons if analysis of variance revealed significant dif-
Fig 1. Systemic interleukin-6 (IL-6; pg/mL) in control group, ischemia-reperfusion group (I/R), and ischemic
preconditioning and ischemia-reperfusion group (IPC I/R). Data represent median (interquartile range). *P .003
compared with control. †P  .01 compared with control. ‡P  .001 compared with ischemic preconditioning and
ischemic-reperfusion.
Fig 2. Systemic tumor necrosis factor-alpha (TNF-alpha; pg/mL) in control group, ischemia-reperfusion group
(I/R), and ischemic preconditioning and ischemia-reperfusion group (IPC I/R). No significant differences between
groups (P  .02). Data represent median (interquartile range).
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ferences. The control value for Dunnett test was designated
as the last measurement obtained at the end of the baseline
period (time 0). Student t test was used for independent
comparisons for parametric data. Kruskal-Wallis analysis of
variance was used in conjunction with Mann-Whitney U
test for nonparametric comparisons. A two-tailed P value of
less than .05 was considered statistically significant.
To assess the degree of association between the vari-
ables, Spearman rank correlation coefficient was calculated.
Significance was taken at the 5% level. Statistical calcula-
tions were performed with SPSS software (Version 9.0,
Microsoft, Redmond, Wash).
RESULTS
Plasma interleukin-6. Plasma interleukin-6 was sig-
nificantly greater during the reperfusion period in the I/R
group as compared with the control group and significantly
attenuated back to control levels in the IPC-treated group.
After 1 hour of reperfusion (t  180 minutes), interleu-
kin-6 levels in the I/R group were highly significantly
elevated (1726.00 pg/mL; 1130.00 to 2130.00 pg/mL)
compared with the control group (303.50 pg/mL; 276.23
to 343.98 pg/mL; P .003), and this rise was significantly
attenuated in the IPC-treated I/R group (213.90 pg/mL;
175.30 to 263.40 pg/mL; P  .001; Fig 1).
Plasma tumor necrosis factor-. Plasma TNF was
not significantly different between groups at any of the time
points measured. With Kruskall Wallis test, at 0 minutes,
P was less than .103, at 120 minutes, P was less than .885,
at 180 minutes, P was less than .106, and at 270 minutes, P
was less than .516 (Fig 2).
Physiologic and hemodynamic variables. Mean val-
ues for heart rate, CVP, and pulmonary capillary wedge
pressure did not alter significantly from baseline through-
out the experimental period. MABP was significantly
greater in both I/R group (P  .01) and IPC-treated I/R
group (P  .001) compared with control during the isch-
emic period (t 0-120 minutes) and remained significantly
elevated in the I/R group during reperfusion period com-
pared with control (P  .001) and IPC-treated I/R group
(P  .01).
MPAP was significantly greater during reperfusion in the
I/R group compared with the control group (P .001) and
the IPC-treated I/R group (P .001). However, the treated
group remained significantly higher than the control (P .02;
Fig 3, A). Arterial partial pressure of oxygen (mm Hg) fell
significantly during the reperfusion period in the I/R
group compared with the control group (P  .05) and the
IPC-treated I/R group (P  .01; Fig 3, B). Alveolar-
arterial O2 gradient values were similar during the ischemia
period but were significantly higher after reperfusion in the
I/R group compared with the control (P .05; Fig 3, C).
This finding suggests impaired alveolar oxygen transport.
This impairment in oxygen transport was prevented in the
IPC-treated I/R group (P  .04).
Lung tissue myeloperoxidase. The lung tissue my-
eloperoxidase concentration was significantly greater in the
I/R group (33.81 units of absorbency/gram dry tissue;
15.65 to 52.66 units of absorbency/gram dry tissue) com-
pared with the control group (7.54 units of absorbency/
gram dry tissue; 0.97 to 8.63 units of absorbency/gram dry
tissue; P  .002). This increase in lung tissue myeloperox-
idase was attenuated in the IPC-treated I/R group (19.91
units of absorbency/gram dry tissue; 18.04 to 20.67 units
of absorbency/gram dry tissue) but still significantly ele-
vated compared with the control group (P  .002; Fig 4,
A).
Lung tissue wet-to-dry weight ratio. The lung wet-
to-dry tissue weight ratio was significantly greater in the
I/R group (10.13; 7.66 to 12.66) compared with the
control group (5.57; 4.54 to 7.37; P .013). This increase
was significantly attenuated in the IPC-treated I/R group
(6.63; 5.93 to 6.94) compared with the untreated I/R
group (P  .015; Fig 4, B).
Whole-blood chemiluminescence. There was a sig-
nificantly greater whole blood phagocytic priming ratio
after 30 minutes of reperfusion (t  150 minutes) in the
I/R group (1.01 0.08) compared with the control group
(0.56  0.11; P  .021) and compared with the IPC-
treated I/R group (0.75  0.08; P  .048). After 2.5
hours of reperfusion (t  240 minutes), the priming ratio
remained significantly greater in the I/R group (0.86 
0.14) compared with the control group (0.26 0.07; P
.054) and the IPC-treated group (0.66  0.08; P  .05).
The priming ratio decreased significantly in the control
group from the start (t  0 minutes; 0.65  0.11) to the
end (t  240 minutes; 0.26  0.07; P  .005). A signifi-
cant increase in priming occurred in the I/R group from t
 0 to t  240 minutes (0.58  0.06) compared with
0.86  0.14 (P  .05; Fig 5).
Whole blood leukocyte counts. No difference was
seen in total whole blood leukocyte count at time zero and
after 240 minutes between the control group (15.55
[10.50 to 24.97] 109 L1 and 23.90 [20.91 to 25.75]
109 L1) and the I/R group (13.56 [12.27 to 21.78] 
109 L1 and 20.94 [14.45 to 26.91] 109 L1). Nor was
there any difference in the neutrophil fraction between the
control group and the I/R group at the start or the end of
the experiment.
DISCUSSION
This study shows that lower limb IPC ameliorates the
cellular and molecular cascade of I/R initiated systemic
inflammation and attenuates acute pulmonary dysfunction
and injury. Invasive hemodynamic measurements and
maintenance intravenous volume supplementation ensured
the large animal model remained normotensive throughout
the experimental period. We used plasma cytokinemia and
luminol-enhanced whole blood chemiluminescence as in-
dices of systemic inflammation and polymorphonuclear
activation, respectively. Lung tissue wet-to-dry weight, my-
eloperoxidase concentration, and pulmonary physiologic
measurements were used as indices of acute lung injury.
Elective lower limb arterial bypass is accompanied by
I/R and associated with local oxidative limb injury26 and a
systemic inflammatory response syndrome that can lead to
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ARDS.27 This study showed that lower limb IPC provided
significant protection against the ischemia-induced and
especially I/R-induced systemic inflammation. It is now
more than 10 years since the phenomenon of IPC was first
noted to protect the ischemic myocardium.7 A number of
neuroendocrine and paracrine triggers are released or op-
erate during preconditioning ischemia. The end-effectors
of classical preconditioning are still under debate, but
Downey and Cohen28 have proposed a scheme whereby
the activated cell surface receptors couple through G-
proteins to phospholipase-C and the formed diacylglycerol
activates protein kinase C (PKC).28 This is supported by
the beneficial effects of pretreating tissues, subsequently
rendered ischemic, with PKC inhibitor staurosporine29 and
more specific PKC inhibitors polymixin B29 and chelery-
thrine.30
Brief circumflex coronary occlusions in canine myocar-
dium induce protection of remote myocardium subtended
by the left anterior descending coronary artery, which
suggests that unidentified diffusible factors or neuronal
mechanisms may influence remote tissue.13 Remote brief
renal ischemia or mesenteric artery occlusion leads to pro-
tection against coronary artery occlusion.15 Even more
interesting is the finding that a brief period of ischemic
stress in the rabbit gastrocnemius muscle can confer remote
protection to the myocardium and reduce infarct size.14
This may suggest that the attenuation of pulmonary dys-
function in our model is not simply the result of reduction
of ischemic limb injury and subsequent systemic inflamma-
tion but that IPC may also confer some remote protection
to the lung or myocardium. Alas, the mechanisms by which
these intraorgan effects are conferred are as yet unknown.
IPC is not a phenomenon specific to cardiac muscle. Moun-
sey et al31 were able to show less necrosis of skeletal muscle
(latissimus dorsi flap) when subjected to prolonged isch-
emia after three brief cycles of antecedent ischemia.8 These
adaptive responses of skeletal muscle have been shown to
be blunted with adenosine receptor blockade and elicited
with A1 receptor activation.32
High levels of TNF-, interleukin-1-	, interleukin-6,
and interleukin-8 have been shown after AAA repair,3,33
and persistent high levels have been correlated with mor-
tality.34,35 TNF- is a potent early proinflammatory medi-
ator released from a variety of cell types in response to
injury. We have not shown significant elevations in plasma
TNF- in this animal study in early response to bilateral
hind limb I/R. This is in keeping with other groups who
have found that the rapid release and subsequent binding of
TNF-makes detection of high plasma levels difficult in the
acute phase.3,27,36 We chose specifically to measure only
biologically active TNF-, and perhaps with an immunoas-
say, the higher levels as reported by other investigators
would have been found.36
We have shown highly significant elevations in plasma
interleukin-6, a reliable indicator of the extent and severity
of inflammation,37 during late ischemia and most markedly
throughout the reperfusion period after bilateral hind limb
ischemia. Whereas IPC before the I/R injury completely
Fig 3. A, Pulmonary artery pressure (mm Hg) in control group,
ischemia-reperfusion group (I/R), and ischemic preconditioning
and ischemia-reperfusion group (IPC I/R). *P .05 compared
with control. †P  .001 compared with control. ‡P  .001
compared with ischemic preconditioning and ischemia-reperfu-
sion. B, Arterial PO2 (mm Hg) in control group, ischemia-reper-
fusion group (I/R), and ischemic preconditioning and ischemia-
reperfusion group (IPC  I/R). *P  .05 compared with control
and ischemic preconditioning and ischemia-reperfusion. †P  .01
compared with control. ‡P  .005 compared with ischemic pre-
conditioning and ischemia-reperfusion. C, Alveolar-arterial gradi-
ent in control group, ischemia-reperfusion group (I/R), and isch-
emic preconditioning and ischemia-reperfusion group (IPC 
I/R). *P  .05 compared with control. †P  .03 compared with
ischemic preconditioning and ischemia-reperfusion. Data repre-
sent mean  standard error of mean. With repeated two-way
analysis of variance (time and group): *P  .0001. †P  .0001.
‡P  .034. With post hoc Dunnett T3 test: *P  .05. †P  .05.
‡P  .01.
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abrogates this increased production of interleukin-6, a sec-
ondary mediator with both proinflammatory and antiin-
flammatory activities, which suggests that prevention of
ischemic limb injury-induced inflammatory activation pre-
vents progression to uncontrolled inflammation in this
model of I/R injury. Cytokines such as interleukin-6 also
have been shown to inhibit polymorphonuclear apoptosis
in vitro and therefore may increase the functional longevity
of polymorphonuclear and the ability to induce tissue inju-
ry.38,39 Although with these data it is not possible to
confirm the source of the cytokines observed, local produc-
tion in the limb is the most likely early source. The contin-
uous rise in plasma concentration of interleukin-6 through-
out the period of reperfusion suggests that reperfusion
injury, rather than ischemia, is the stimulus for the cytokine
production. Further, this supports the finding of others
that interleukin-6 production is proportional to the extent
of reperfusion injury.38
Increased circulating polymorphonuclear priming and
activation have been shown after abdominal aortic aneu-
rysm repair.27 Studies into polymorphonuclear activity
show that phagocytosis is upregulated with cytokines
TNF-, interleukin-6, and interleukin-8.40,41 The process
whereby exposure to a plasma factor increases the capacity
of polymorphonuclear to produce reactive oxidant species,
in response to a secondary stimulus, is called priming.
Priming agents are thought to be central to the role of
polymorphonuclear-mediated antimicrobial activity and
tissue damage.42 In reperfusion injury, a variety of cyto-
kines and mediators may be responsible for priming neu-
trophils, increasing the production of harmful oxidants,
and promoting systemic inflammatory response syndrome.
Fig 4. A, Lung myeloperoxidase (U/g) in control group, ischemia-reperfusion group (I/R), and ischemic precon-
ditioning and ischemia-reperfusion group (IPC  I/R). *P  .01 compared with control. †P  .02 compared with
ischemic preconditioning and ischemia-reperfusion. B, Lung wet-to-dry ratio in control group, ischemia-reperfusion
group (I/R), and ischemic preconditioning and ischemia-reperfusion group (IPC I/R). *P .0001 compared with
control. Data represent median (interquartile range).
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Luminol-dependent chemiluminescence of whole blood
was developed to estimate the phagocytic function of gran-
ulocytes and the serum opsonic activity simultaneously. It
measures reactive oxygen species production and neutro-
phil degranulation, which is specific and azurophilic.42,43
We have shown in our model increased circulating whole
blood phagocytic cell priming after lower limb I/R injury
and that prior IPC can attenuate this increase. This de-
creased polymorphonuclear priming and therefore poten-
tial for respiratory burst-induced tissue injury may perhaps
explain the decreased systemic inflammatory response and
pulmonary injury. Local skeletal muscle IPC has been
shown to modulate neutrophil adhesion and emigration.44
No study, until now, has shown a reduction in circulating
neutrophil priming in response to skeletal muscle IPC.
In this study, the development of remote pulmonary
dysfunction was observed only after reperfusion, with de-
velopment of hypoxemia, pulmonary hypertension, and
impaired oxygen transport. Humoral or cellular mediators
or both may be implicated. Elevated levels of lung tissue
myeloperoxidase and wet-to-dry weight ratio suggest a
neutrophil-mediated acute lung injury. The prevention of
this acute pulmonary dysfunction in the IPC-treated group
suggests a role for limb reperfusion-induced circulating
neutrophil activation in the development of this lung in-
jury. Of interest, the myeloperoxidase concentration in the
IPC-treated I/R group was elevated compared with con-
trol, although it did not reach significance. However, there
was significantly less edema in the IPC-treated group, and
this may suggest that neutrophils are still sequestering in
the lung, although because these circulating neutrophils are
less primed, they induce less tissue injury. Our findings are
in agreement with previous reports of a varying degree of
pulmonary dysfunction, characterized by increased micro-
vascular permeability and leukocytic sequestration within
the lung.4 Early signs of ARDS, which carries a high
mortality rate, have been reported within hours of aortic
declamping in patients who undergo abdominal aortic an-
eurysm repair4 and in animal models of reperfusion inju-
ry.36 We witnessed a significant degree of pulmonary hy-
pertension in our I/R group associated with the impaired
alveolar oxygen transport and acute lung injury. Varying
degrees of pulmonary hypertension have been shown in
patients with ARDS.45 The importance of polymorphonu-
clear in acute lung injury after limb I/R has been confirmed
in leukopenic models.1 Acute lung injury has been shown
in polymorphonuclear depleted animals.46 However, this is
less severe. This injury is probably caused by vasoactive
mediators, such as thromboxane A2 and leukotriene B4,
released from the limb on reperfusion.5 The lung injury
after remote limb I/R is primarily the result of neutrophil
adherence, sequestration, and subsequent respiratory burst-
induced oxidative injury. This is supported by the observation
that lung injury can be attenuated with prevention of neutro-
phil adherence with anti-CD18 monoclonal antibodies or
oxidative injury with antioxidant preloading.47
The most readily modifiable trigger of IPC may be
adenosine. Increased local levels of adenosine achieved with
draflazine and acadesine have been shown to potentate the
effects of IPC in ischemia-induced arrhythmia in pigs.
Infusing adenosine intravenously has been shown to repro-
duce the protective effects of IPC in a rat skeletal muscle
ischemia model.48 Attempts to modulate the end-effector
of IPC have spawned therapeutic research, and already
several KATP channel openers have been developed as anti-
ischemic agents, most notably nicorandil.
In conclusion, we have shown herein that IPC partially
protected against lower limb I/R-induced systemic inflam-
mation and acute lung injury. Future work will be needed
to identify the exact mechanisms responsible for IPC in the
prevention of systemic cytokinemia, phagocytic cell prim-
ing, and acute lung injury to determine whether or not such
Fig 5. Circulating phagocytic cell priming (% maximum) in control group, ischemia-reperfusion group (I/R), and
ischemic preconditioning and ischemia-reperfusion group (IPC  I/R). *P  .05 compared with control. †P  .01
compared with ischemic preconditioning and ischemia-reperfusion. Data represent mean  standard error of mean.
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protection will translate into an improved clinical outcome
in situations in which iatrogenic lower limb I/R is likely to
occur. There is a growing body of evidence that supports a
beneficial role for IPC before any planned ischemia-induc-
ing surgical procedure in the prevention of local cardiac or
skeletal muscle injury. This may represent an important
preventative measure in those patients who are often elderly
with coexistent cardiovascular and renal dysfunction. In
conclusion, we have shown that prior IPC can reduce the
production of interleukin-6 and also significantly attenu-
ates the remote acute pulmonary dysfunction seen after
hind limb I/R injury. This is associated with a reduction
in circulating neutrophil priming. We therefore conclude
that IPC attenuates the inflammatory response and lung
injury associated with limb I/R by limiting reperfusion
injury.
We thank Professor C. Patterson, PhD, Department of
Epidemiology, Queen’s University Belfast, for his statistical
advice.
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